Security key
114082209
Ernexa Therapeutics Inc. - Common Stock (ERNA)
CUSIP: 114082209
Q2 2024 13F Holders as of 30 Jun 2024
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 390,079
- Total 13F value
- $712,390
- Share change
- -19,127
- SEC-reported price per share
- $1.83
- Number of holders
- 19
- Value change
- -$47,643
- Number of buys
- 5
- Number of sells
- 6
- Shares outstanding
- 1,166,181
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
19
Top holders
10
ERNA full security history
Ownership snapshot
Full 13F holder table
Ernexa Therapeutics Inc. SEC filings
Ernexa Therapeutics Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of ERNA - Ernexa Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Freebird Partners LP
Disclosed value leader
Freebird Partners LP
Comparable rows
0/15
Latest evidence
31 Mar 2024
3/4/5
13F
Highest disclosed value: $1,503,337
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Freebird Partners LP has the largest disclosed position value at $1.5M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Freebird Partners LP's linked filing trail.
Disclosed position value
Top 5
Freebird Partners LP
$1.5M
George P. Denny III
$1.13M
John D. Halpern
$1.12M
Nicholas J. Singer
$962.3K
Cypress Point Wealth Management, LLC
$226.5K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Freebird Partners LP |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
$1,503,337
2,774,627 shares
mixed-class rows
|
— | 14 Dec 2023 |
| George P. Denny III |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$1,134,456
457,442 shares
|
— | 02 Dec 2022 |
| John D. Halpern |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
$1,118,891
1,123,006 shares
mixed-class rows
|
— | 02 Dec 2022 |
| Nicholas J. Singer |
3/4/5
Director
|
—
mixed-class rows
|
$962,330
954,608 shares
mixed-class rows
|
— | 02 Dec 2022 |
| Cypress Point Wealth Management, LLC |
13F
Company
|
—
denominator unverified
|
$226,500
94,375 shares
|
— | 31 Mar 2024 |
| Roger Sidhu |
3/4/5
Chief Medical Officer
|
—
mixed-class rows
|
$200,012
80,650 shares
mixed-class rows
|
— | 20 Sep 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
19
Shares
390,079
Rows available
19
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
22
Q2 2024 holders
19
Holder diff
-3
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|